35 completed, 7 unknown, 1 not yet recruiting, 1 recruiting. 46 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Completed 35, Unknown 7, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Fluticasone: new trials by email Literature Review of Fluticasone trials Research Report on Fluticasone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis Fluticasone Propionate (FP) 10% Nasal Insert - Chronic Allergic Rhinitis | Phase 1 | Not yet recruiting | Dianosic | 25 | 2026-11-01 | 2026-11-05 |
| Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old TEV-56248, Fp MDPI - Asthma | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 30 | 2024-05-16 | 2026-08-04 |
| Advair HFA in Healthy and HAPE Predisposed Subjects Advair HFA, Placebo - Altitude Edema | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 60 | 2023-12-12 | 2025-09-22 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 36 | 2022-05-11 | 2022-05-31 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 18 | 2021-10-01 | 2021-10-20 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-08-13 | 2021-08-26 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-01-18 | 2021-04-20 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-09-22 | 2021-01-20 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 14 | 2020-09-01 | 2021-03-09 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 14 | 2020-08-24 | 2021-01-20 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-07-01 | 2021-03-09 |
| A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals), Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK), Activated Charcoal suspension - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 36 | 2019-10-01 | 2020-07-07 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2019-05-21 | 2019-09-10 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC) Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals, SERETIDE DISKUS® 250/50 inhalation powder/GSK, Activated Charcoal suspension - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 36 | 2019-03-12 | 2019-06-05 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2019-01-23 | 2019-03-27 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2018-11-20 | 2018-12-28 |
| Study of REGN3500 and Dupilumab in Patients With Asthma REGN3500, Dupilumab, Placebo - Asthma, Allergic | Phase 1 | Completed | Regeneron Pharmaceuticals | 32 | 2017-06-15 | 2020-01-18 |
Showing 20 of 46. Sign in to see all of them.
Asthma (16) · Pulmonary Disease, Chronic Obstructive (6) · Rhinitis, Allergic (5) · Altitude Sickness (1) · Diabetes Mellitus (1) · Hypoxia (1) · Rhinitis, Allergic, Perennial (1) · Rhinitis, Allergic, Seasonal (1)
Respirent Pharmaceuticals Co Ltd. (16) · GlaxoSmithKline (5) · Pfizer (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Egalet Ltd (2) · Intech Biopharm Ltd. (2) · MEDA Pharma GmbH & Co. KG (2) · Merck Sharp & Dohme LLC (2) · Dey (1) · Dianosic (1) · Joseph Dohar, MD (1) · Kindeva Drug Delivery (1) · Mannkind Corporation (1) · Mundipharma Research Limited (1) · Optinose US Inc. (1)
Greece (16) · United States (9) · United Kingdom (8) · Germany (4) · Australia (2) · Taiwan (2) · Ireland (1) · Netherlands (1) · South Korea (1)
Ioannis Stefanidis, Professor (9) · Chrysoula Doxani, MD, MSc, PhD (6) · Christine Kolb (2) · W K Chang, M.D (2) · Adrian J Stewart, BM, MRCGP, MFPM (1) · Anders H. Boss (1) · Chrysoula Doxani, Dr. (1) · Cyril Clarke, BSc MB BS MFPM (1) · In-Jin Jang, PhD (1)
PMID 24168756, PMID 28626983, PMID 28933971, PMID 31732149
2016 (1)